肾移植与活体供肾者风险评估中的基因检测
本研究对231例肾移植受者和46例前瞻性活体供肾者进行409个慢性肾脏病相关基因的外显子测序,并回顾122例移植后出现不良肾脏结局的供肾者。受者中23%检出致病或可能致病变异,其中37%的基因诊断导致表型重新分类;前瞻性供肾者携带率为4%,而回顾性不良结局供肾者携带率达19%。结论支持对高风险供肾者进行靶向基因检测而非普遍筛查。
要点
- 肾移植受者基因检测诊断率高,23%检出致病或可能致病变异。
- 基因诊断使37%的受者重新分类为不同CKD表型。
- 不良结局供肾者P/LP变异携带率19%,支持靶向检测高危供者。
核心结论
- 基因检测在肾移植受者中诊断率高,常重新分类CKD病因,支持其诊断价值。
- 前瞻性无症状活体供肾者普遍基因检测产出率为4%,但样本量有限。
- 移植后出现不良肾脏结局的供肾者中P/LP变异携带率高达19%,提示靶向检测高风险供者可能优于普遍检测。
研究设计与样本
- 对231例肾移植受者和46例前瞻性活体供肾者进行409个CKD相关基因的外显子测序。
- 回顾性评估122例移植后出现不良肾脏结局的活体供肾者,不良结局定义为高血压、eGFR<60 mL/min/1.73m2或尿白蛋白/肌酐比≥3 mg/mmol三项中至少两项。
主要发现
- 23%的受者检出致病或可能致病(P/LP)变异,最常见于囊性肾病和肾小球病相关基因。
- 在基因诊断的受者中,37%在检测后重新分类为不同表型。
- 前瞻性活体供肾者中4%携带P/LP变异。
- 回顾性不良肾脏结局供肾者中19%携带P/LP变异。
关键数值与推荐
- 肾移植受者P/LP变异检出率23%。
- 基因诊断受者表型重新分类率37%。
- 前瞻性活体供肾者P/LP变异携带率4%。
- 不良肾脏结局供肾者P/LP变异携带率19%。
- 不良肾脏结局定义:高血压、eGFR<60 mL/min/1.73m2、尿白蛋白/肌酐比≥3 mg/mmol三项中至少两项。
临床怎么用
- 对肾移植受者考虑基因检测以明确CKD病因并指导表型分类。
- 对高风险活体供肾者(如有不良结局风险因素)优先进行靶向基因检测,而非普遍筛查。
- 供肾者选择需平衡供者安全与公平可及性。
局限性
- 前瞻性活体供肾者队列样本量有限。
- 需进一步评估靶向检测策略能否适当平衡供者安全与公平可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The cause of kidney failure in kidney transplant recipients remains unknown in 20-45% of cases. Outcomes for living kidney donors (LKDs) are generally excellent, with only 8% experiencing complications post-donation. Here, we hypothesize that genetic testing could identify a genetic etiology in at least 20% of recipients and inform risk stratification in LKDs. METHODS: Genetic testing was performed in 231 transplant recipients and 46 prospective LKDs by means of exome sequencing of 409 chronic kidney disease (CKD)-associated genes. We also assessed 122 retrospective LKDs who developed adverse kidney outcomes post-donation which were defined by at least two of the three criteria: hypertension, a glomerular filtration rate under 60 mL/min/1.73m2, or a urine albumin to creatinine ratio of 3 mg/mmol or more. RESULTS: Pathogenic or likely pathogenic (P/LP) variants were identified in 23% of recipients, most commonly involving genes associated with cystic kidney disease and glomerulopathies. Among the recipients with a genetic diagnosis, there was a 37% rate of reclassification to a different phenotype post genetic testing. Among prospective LKDs, 4% had P/LP variants. In the retrospective cohort of LKDs with adverse kidney outcomes post donation, 19% carried P/LP variants. CONCLUSIONS: Genetic testing yielded a high diagnostic rate and frequently reclassified CKD etiology in transplant recipients, underscoring its diagnostic utility. Universal genetic testing of asymptomatic LKDs had a yield of 4%, although our prospective LKD cohort had limited sample size. In contrast, high proportion of LKDs with adverse kidney outcome post-donation were found to carry P/LP variants in CKD-associated genes. Our findings suggest that targeted genetic testing of high-risk donors may be a preferred over universal testing strategy to optimize donor selection in LKDs. However, further evaluation is warranted to ensure this approach appropriately balances donor safety with equitable access.
引用
- Schott C, Relouw S, Arnaldi M, et al. Genetic testing in kidney transplantation and living kidney donor risk assessment. Kidney Int. 2026. PMID: 41903706. doi:10.1016/j.kint.2026.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。